BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Related Party | - | - | - | 0 | 0 | 0 | - | - | - | |||||
Common Class A | - | - | - | 0 | 19 | 18 | 18 | 0 | 1 | |||||
Common Class B | - | - | - | 0 | 5 | 0 | 0 | 0 | 5 | |||||
Preferred Stock | 0 | 0 | 0 | - | 0 | 23 | 36 | - | - | |||||
Assets Current | ||||||||||||||
Assets | ||||||||||||||
Cash And Cash Equivalents At Carrying Value | 53 | 374 | 409 | 1 | 1 | 31 | 2 | 2 | 2 | |||||
Prepaid Expense Current | - | - | - | - | - | - | - | 0 | 0 | |||||
Prepaid Taxes | - | - | - | - | 0 | 0 | 0 | - | - | |||||
Marketable Securities Current | 200 | 52 | 60 | - | - | 125 | - | - | - | |||||
Accounts And Other Receivables Net Current | 0 | 0 | - | - | - | 0 | - | - | - | |||||
Prepaid Expense And Other Assets Current | 14 | 7 | 7 | 0 | - | 3 | - | - | - | |||||
Prepaid Insurance | - | - | - | 0 | 0 | 0 | 0 | - | - | |||||
Assets Current | 267 | 432 | 476 | 1 | 1 | 159 | 2 | 2 | 2 | |||||
Prepaid Expense Noncurrent | - | - | - | - | - | - | - | - | 0 | |||||
Assets Held In Trust Noncurrent | - | - | - | 197 | 194 | 192 | 190 | 188 | 185 | |||||
Marketable Securities Noncurrent | 137 | - | - | - | - | - | - | - | - | |||||
Property Plant And Equipment Net | 1 | 1 | 1 | - | - | 0 | - | - | - | |||||
Operating Lease Right Of Use Asset | 2 | 2 | 2 | - | - | 0 | - | - | - | |||||
Other Assets Noncurrent | 11 | 13 | 5 | - | - | 5 | - | - | - | |||||
Restricted Cash Noncurrent | 0 | 0 | 0 | - | - | 0 | - | - | - | |||||
Assets | 418 | 448 | 485 | 197 | 196 | 164 | 192 | 190 | 188 | |||||
Liabilities And Stockhold… | ||||||||||||||
Accrued Liabilities Current | - | - | - | - | 2 | 0 | 0 | 0 | 0 | |||||
Liabilities Current | ||||||||||||||
Accounts Payable And Accrued Liabilities Current | - | - | - | 3 | - | - | - | - | - | |||||
Accounts Payable Current | 12 | 1 | 4 | - | - | 3 | - | - | - | |||||
Accrued Employee Benefits Current | 2 | 6 | 4 | - | - | 4 | - | - | - | |||||
Accrued Professional Fees Current | 1 | 1 | 2 | - | - | 1 | - | - | - | |||||
Notes Payable Current | 1 | 1 | 1 | - | - | 0 | - | - | - | |||||
Operating Lease Liability Current | 1 | 1 | 1 | - | - | 0 | - | - | - | |||||
Other Accrued Liabilities Current | 1 | 0 | 0 | - | - | 0 | - | - | - | |||||
Participating Mortgage Loans Participation Liabili… | - | 0 | - | - | - | 3 | - | - | - | |||||
Liabilities Current | 43 | 35 | 36 | 3 | 2 | 20 | 0 | 0 | 0 | |||||
Deferred Compensation Liability Classified Noncurr… | - | - | - | - | - | - | - | - | 6 | |||||
Operating Lease Liability Noncurrent | 2 | 2 | 2 | - | - | 0 | - | - | - | |||||
Liabilities | 45 | 37 | 38 | 8 | 7 | 20 | 6 | 6 | 6 | |||||
Temporary Equity Carrying Amount Attributable To P… | - | - | - | - | - | - | - | - | 185 | |||||
Stockholders Equity | ||||||||||||||
Common Stock Value | 0 | 0 | 0 | - | - | 0 | - | - | 0 | |||||
Additional Paid In Capital | 772 | 768 | 764 | - | - | 44 | - | - | - | |||||
Retained Earnings Accumulated Deficit | -399 | -357 | -318 | -7 | -6 | -223 | -4 | -3 | -3 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -1 | 0 | 0 | - | - | 0 | - | - | - | |||||
Stockholders Equity | 372 | 411 | 447 | -7 | -200 | -179 | -159 | -3 | -3 | |||||
Liabilities And Stockholders Equity | 418 | 448 | 485 | 197 | 196 | 164 | 192 | 190 | 188 | |||||
Redeemable Convertible Preferred Stock | 0 | 0 | 0 | - | 36 | 36 | 36 | - | - | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 0 | 5 | 5 | 5 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | - | - | 0 | - | - | - | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | - | - | 0 | - | - | - | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | - | - | 0 | - | - | - | |||||
Common Stock Shares Authorized | 500 | 500 | 500 | - | - | 496 | - | - | - | |||||
Common Stock Shares Issued | 80 | 80 | 79 | - | - | 57 | - | - | - | |||||
Shares Outstanding | 80 | 80 | 79 | - | - | 57 | - | - | - | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.94% | -0.25% | - | - | - | - | - | - | - | - | - | - |
| 2025 | 0.37% | -1.94% | -3.83% | -15.28% | 9.45% | 6.86% | 8.39% | -2.69% | -7.21% | -10.21% | -11.22% | -13.55% |
| 2024 | -0.77% | -1.26% | 0.48% | 0.05% | 0.24% | 1.83% | -0.71% | 4.42% | 1.66% | 1.03% | 1.50% | 0.47% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 50+ calculated metrics
Subscribe to unlock 17+ years of data and 50+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
BridgeBio Oncology Therapeutics, Inc. (BBOT) — SEC Financial Statements & Analysis
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a pharmaceutical preparations company, incorporated in DE. BridgeBio Oncology Therapeutics, Inc. trades on BBOT: Nasdaq as: BBOT. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), BridgeBio Oncology Therapeutics, Inc. reported a 64.66% year-over-year revenue growth, a Debt-to-Equity ratio of 0.12x, a Price-to-Sales (P/S) ratio of 0.16x (TTM), a Price-to-Book (P/B) ratio of 0.01 (TTM), at a market cap of $2.15M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 64.66%
- Debt To Equity
- 0.12x
- P/S TTM
- 0.16x
- P/B TTM
- 0.01
- Market Cap
- $2.15M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BridgeBio Oncology Therapeutics, Inc. in?
BridgeBio Oncology Therapeutics, Inc. (BBOT) operates in the Pharmaceutical Preparations industry.
What is BBOT's market cap?
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a market capitalization of $2.15M as of 2026-03-31.
What exchange does BBOT trade on?
BridgeBio Oncology Therapeutics, Inc. (BBOT) trades on the BBOT: Nasdaq.
Where is BridgeBio Oncology Therapeutics, Inc. incorporated?
BridgeBio Oncology Therapeutics, Inc. is incorporated in DE.